Summary

• More than 10 million EU medical procedures use radioisotopes each year, particularly in oncology and cardiology.
• Europe is the world’s leading producer and exports about half its output, yet parts of the supply chain depend on ageing facilities and overseas suppliers.
• The European Radioisotope Valley Initiative will coordinate investment while targeting strategic dependence, particularly on Russia.

Europe leads the world in medical-radioisotope production, yet ageing facilities and dependence on overseas suppliers have left enough weakness in the chain for the European Commission to treat nuclear medicine as an industrial resilience problem rather than simply a healthcare procurement issue.

The European Radioisotope Valley Initiative, unveiled on 10 September, is intended to guide investment into production capacity, reinforce the supply chain, and reduce strategic dependencies on third countries, particularly Russia.

More than 10 million medical procedures using radioisotopes are carried out in the EU each year, mainly in oncology and cardiology. Europe is already the world’s largest producer and exports around half its output, which makes the concern less about creating an industry from scratch than ensuring existing capacity does not erode faster than it can be replaced.

Unlike many medical products, radioisotopes create unusually unforgiving logistics because radioactive decay begins immediately. Some products cannot be stockpiled for long periods, so reactors, accelerators, processing facilities, transport, and hospitals have to operate as a coordinated chain.

Production strength hides upstream dependencies

A strong position in finished isotope production does not mean every part of the process is secure. The Commission points to ageing production facilities, exposure to foreign suppliers, and competition from alternative producers that could divert future investment away from Europe.

Several facilities supporting nuclear medicine were built decades ago, while replacement projects face the long timelines associated with nuclear regulation, specialised construction, highly skilled staff, and capital-intensive equipment. A shortage cannot therefore be solved quickly after a reactor or processing site reaches the end of its useful life.

Russia adds another strategic element. The REPowerEU roadmap identified medical-radioisotope capacity among the dependencies Europe should reduce, extending the effort to unwind Russian exposure beyond energy imports into specialist nuclear materials and services.

Medical supply also makes resilience harder to express solely through cost. Buying from the cheapest available source can work until geopolitical disruption, plant maintenance, transport interruption, or ageing infrastructure removes capacity that cannot be replaced in time for patient treatment.

The situation resembles other European supply-chain debates around semiconductors, batteries, critical minerals, and cloud infrastructure, although radioisotopes add the constraint of physical decay. A digital service can sometimes be shifted elsewhere when a supplier fails; an isotope delayed for long enough can become unusable.

ERVI is a framework rather than one new plant

The initiative does not itself announce a centrally owned European production facility or one headline budget. Instead, Brussels intends it to coordinate future investment and provide a strategic structure around decisions made by member states, operators, healthcare systems, and investors.

ERVI follows a feasibility study published earlier this year and builds on the Commission’s existing SAMIRA programme for medical uses of ionising radiation. The work has included consultation with governments and industry about future production needs and the infrastructure required to maintain supply.

That coordination could reduce the risk of several countries assuming somebody else will replace ageing capacity, although it cannot remove the underlying commercial challenge. New reactors, accelerators, and processing facilities need financing, predictable demand, regulatory approval, and long operating lives to justify their cost.

Europe’s export position gives operators access to a larger market but also exposes them to international competition. If new facilities elsewhere offer attractive economics while European projects remain delayed, expertise and investment can move even while current production statistics continue to look strong.

Nuclear medicine is also expanding

The investment calculation is further complicated by changes in treatment. Radioisotopes are established diagnostic tools, but targeted radiopharmaceutical therapies are creating additional demand for materials used to attack cancers more precisely.

That can place different requirements on production and distribution because newer therapeutic isotopes may depend on specialist facilities or supply chains that are less mature than those supporting established diagnostic products.

Healthcare systems therefore need to plan not only for replacement of current infrastructure but for a market whose clinical demand may change. Under-investment risks shortages, while excessive or badly coordinated investment can leave expensive nuclear assets without enough utilisation.

The Commission’s framework attempts to manage that uncertainty at European level, where production and treatment already cross national borders. A reactor in one country can supply hospitals in several others, making purely national resilience plans difficult to reconcile with the actual supply chain.

Whether ERVI changes investment decisions will become apparent only over a longer period. Strategic documents cannot keep an ageing facility operating, while identifying dependence on Russia does not automatically produce a replacement supplier with the same technical capabilities.

Europe nevertheless starts from a position worth protecting. It already has production infrastructure, specialist expertise, and a large internal healthcare market, but those advantages can deteriorate if investment decisions are repeatedly deferred. ERVI is an attempt to make those decisions before an ageing asset or external disruption turns a manageable dependency into a shortage experienced directly by hospitals.